SS-31 (Elamipretide)

Scientific Overview, Mechanism, Clinical Use and Evidence

Scientific Overview

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide designed to improve mitochondrial function by interacting with cardiolipin in the inner mitochondrial membrane. It has been investigated across multiple mitochondrial and metabolic indications and, as of 2025, has received U.S. FDA accelerated approval for treatment of Barth syndrome under the brand Forzinity (elamipretide) injection.

Mechanism of Action

Elamipretide selectively associates with cardiolipin, a phospholipid enriched in the inner mitochondrial membrane:

• Stabilizes mitochondrial cristae architecture
• Improves electron transport chain efficiency
• Reduces oxidative stress and reactive oxygen species
• Increases ATP production and mitochondrial bioenergetics

Mechanistic work also supports a broader interaction landscape at the inner mitochondrial membrane consistent with modulation of mitochondrial function and resilience.

Biological and Clinical Effects

Preclinical studies demonstrate improvements in mitochondrial respiration, reduced reactive oxygen species, and functional benefits in models of mitochondrial dysfunction. In clinical development, elamipretide has been studied in primary mitochondrial myopathy and other mitochondrial disorders. FDA accelerated approval (2025) for Barth syndrome reflects regulatory recognition of clinical benefit in a rare mitochondrial disease context.

Time of Use / Treatment Duration

In published studies, treatment durations commonly range from 12 to 24 weeks for randomized phases, with extension studies lasting much longer (including multi-year open-label periods). Clinical benefit in certain endpoints may require continued therapy; discontinuation effects can vary by condition and endpoint.

Safety, Tolerability, and Precautions

Across clinical studies, elamipretide is commonly associated with injection-site reactions. Gastrointestinal symptoms and headache have also been reported. Use should be approached cautiously in complex multisystem disease, and monitoring should be tailored to the indication. Precautionary exclusions include pregnancy and lactation. For approved indications, contraindications and warnings should be followed per label.

Detailed References

Tung C, et al. (2025). Elamipretide: A review of its structure, mechanism of action, and clinical development. PubMed.

Chavez JD, et al. (2020). Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences (PNAS).

Allingham MJ, et al. (2021). Phase 1 clinical trial of elamipretide: once-daily 40 mg subcutaneous dosing for 24 weeks. PMC.

ClinicalTrials.gov. NCT03323749. Safety and efficacy of elamipretide with 40 mg once-daily subcutaneous dosing and long-term extension.

U.S. FDA. (2025, Sep 19). FDA grants accelerated approval to Forzinity (elamipretide) injection as first treatment for Barth syndrome.

LaValle J. The Complete Guide to Peptides / Peptide Therapy. Clinical-functional medicine framing for mitochondrial support.

Posology (Clinical Practice–Oriented)

Dosing should follow approved labeling when used for an approved indication.

Published clinical trial regimens commonly used elamipretide at 40 mg subcutaneously once daily (1 mL injection) for 12–24 weeks, with some protocols extending into long open-label phases.

For Barth syndrome (Forzinity), dosing should follow the official prescribing information and patient-specific factors (e.g., weight thresholds and monitoring requirements).

Use for other mitochondrial or metabolic goals should be conservative and physician-directed.

Clinical Practice Framing

From a scientific-medical perspective, SS-31/elamipretide is best framed as a mitochondria-directed therapy with a growing clinical evidence base in mitochondrial disease. Mitochondrial-targeted peptides are positioned as adjuncts to foundational interventions (nutrition, sleep, exercise tolerance, oxidative stress support) rather than stand-alone solutions.

The peptides described in this material are intended strictly for research purposes only. They are not approved for human or veterinary use, clinical application, diagnosis, treatment, or prevention of any disease.

Any research involving these compounds must be conducted in compliance with applicable laws and regulations in the country where the research is performed, including prior approval by a duly constituted Ethics Committee or Institutional Review Board (IRB), where required.

RegenPept acts solely as a supplier of research-grade materials and assumes no responsibility or liability for the design, conduct, regulatory compliance, interpretation, or outcomes of any research involving these products.

Any dosage, administration protocols, or related information contained in this material are derived from publicly available scientific literature and are provided strictly for informational purposes. Such information does not constitute medical advice, therapeutic recommendation, or endorsement of any specific use by RegenPept.